{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"31574.57","value":"91219.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"107"}],"units":"Participants"}],"description":"Crossover C2D1 visit was combined with C2D1 visit for the analysis of this endpoint.","dispersionType":"Standard Deviation","groups":[{"description":"Participants received AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle, until occurrence of disease progression, unacceptable toxicity, confirmed pregnancy, death, subject withdrawal, lost to follow-up, or the sponsor ended the study. Participants who experienced disease progression and received placebo were allowed to cross over to receive AG-120 500 mg, tablet, orally, QD in each 28-day treatment cycle.","id":"OG000","title":"Randomization Phase AG-120 Plus Cross Over Phase AG-120"}],"paramType":"MEAN","populationDescription":"PK Analysis Population consisted of all participants who were enrolled and received at least one dose of study medication (AG-120) with sufficient plasma sample data to assess PK parameters. Number analyzed is the number of participants with data available for analyses at the specified time point.","reportingStatus":"POSTED","timeFrame":"Post-dose of Cycle 2 Day 1 (each cycle = 28 days)","title":"Area Under the Plasma Concentration-time Curve From Time Zero to 24 Hours (AUC0-24)","type":"SECONDARY","unitOfMeasure":"h*ng/mL"}